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Abstract
Cryotherapy, also known as cryosurgery or cryoablation, is a common dermatological 
treatment that is an expanded area from benign to malignant lesions. The system has 
been designed as a localized freezing cold that causes the destruction of cell integrity. 
The treatment has been also used for all ages, which is not required to have a condition of 
wellness. It is convenient, fast, and easy to apply in clinics, and there is no need for anes-
thesia. Additionally, multiple lesions are also cured in the same sessions. After the treat-
ment, recovery period has not taken much longer and also has simple adverse effects, 
which are tolerable. Lastly, cryotherapy has gained excellent cosmetic results. It is highly 
effective for actinic keratosis and is the treatment of choice for most old patients who 
show poor cooperation and recurrent multiple lesions. Additionally, due to increasing 
premalignant lesions all over the world associated with increasing age, it is a consider-
able choice for lentigo maligna and Bowen’s disease. In non-melanoma skin cancers, it is 
also the most important option in patients who do not undergo surgery and when other 
options are not appropriate. In this chapter, the use of cryotherapy for premalignant and 
malignant cutaneous disorders has been mainly focused.
Keywords: cryotherapy, cryosurgery, treatment, cutaneous, premalignant, malignant, 
actinic keratosis, non-melanoma skin cancers
1. History
Cryotherapy (also called cryosurgery or cryoablation) method was produced by James Arnott 
in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells 
destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological 
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indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the 
use of this method in different diseases such as pigmented nevus and lupus. In addition, he has 
published a case series of skin cancers in different face regions. Beyond these series, he described 
that the spray method is superior to cotton swab. Lortat Jacobs and Solente first described the 
name “La Cryotherapie,” which compounds with carbon dioxide in 1930s. Earlier in 1960s, 
Cooper and Lee introduced the cryosurgery technique as cooper apparatus cooled using liquid 
nitrogen. In the course of time, this technique has improved and has transformed in the present 
day [1, 2].
2. Mechanisms of action in cutaneous cryotherapy
If we consider the mechanism, mainly −196°C was required to transmit the cold over tissues. 
When freezing shock has just reached tissues due to intracellular hyperosmotic conditions, 
damage of cells begin. Rapid electrolyte transfer has started, thereby increasing the intracel-
lular component, which has been incriminated for the damage of cell proteins and enzyme 
systems. Thrombosis has been observed in microcirculation system as a factor of irreversible 
tissue loss even in mild freeze. Furthermore, inflammation converts necrosis finally [3, 4].
The size of ice crystals is important, and larger crystals cause greater damage. Rapid freez-
ing speeds are required in the treatment of malignant lesions where cryosurgery is required. 
Speed is also required, and repetitions of sequence increase cell deaths. This issue is also use-
ful for malignant ones [3, 4].
The mechanism of extinction has referred melanocyte between −4 and −7°C, whereas kera-
tinocyte and connective tissue cell destruction occur only at −20°C. Regarding basic mecha-
nism, this technique has been applied in lower temperature, which is also available for such 
dermatological conditions having high success rates [3].
3. Techniques of cutaneous cryotherapy
Technical modalities have been divided into three main groups which include contact, spray, 
and intralesional types. The frequency of these methods, which are written in an order, 
extends to benign and malignant lesions. Contact method is applied using a cotton applicator 
that is usually used for common warts. The most widely used technique in dermatology clinic 
is the spray form directed from a 90° angle at a distance of 1–2 cm. The newly developed one 
is the intralesional technique mainly used in malignant lesions and keloid scars. Intralesional 
cryotherapy is the preferred choice than other methods due to preserving epidermis and 
absence of hypopigmentation and scarring. Local anesthesia is usually not necessary but may 
be recommended if large areas are being treated [5].
Cryotherapy and cryosurgery are the modalities used interchangeably. If we enlighten the 
terminology, cryotherapy accurately freezes the lesion, but when combined with curettage, it 
gets its name as cryosurgery. Nevertheless, most clinicians unintentionally confuse each other.
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4. Indications of cutaneous cryotherapy
The most common indications change from country to country due to the mean age of popu-
lation, education levels, and capability of the physicians. In a comprehensive study conducted 
between 1993 and 2010 in the USA, the cryotherapy method is the most frequently used in 
actinic keratosis (AK), common warts, and seborrheic keratosis [6]. An article investigated 
in our country suggested that the most common indications are common warts, anogenital 
warts, callosity, and AK. An interesting point of this article is the use of cryotherapy on leish-
mania cases, and it achieved good results [7]. Generally, authors receive attention regarding 
physicians who have to determine how many cycles and how long duration are required for 
each lesion. Especially, some of the skin areas having a thin dermis should take lesser freezing 
time even if malignant lesions should be repeated for more than one cycle. Additionally, cryo-
therapy is also reliable in pregnant women with anogenital warts. As expected, a combination 
with various therapeutical methods increases the success rate. Different dermatological indi-
cations of cryotherapy are summarized in Table 1. Our clinical experiences in cryotherapy of 
seborrheic keratosis and verruca plantaris (which are commonly seen as benign lesions) are 
also demonstrated in Figures 1 and 2, respectively.
Cryotherapy is also being discussed as an alternative to surgery in patients with premalig-
nant or malignant lesions. The interesting point involved in our review is that the frequency 
of using cryotherapy has doubled compared to the first 10 years (1988–2000) than the second 
Benign lesions Premalignant lesions Malignant lesions
Acne scars Actinic keratosis Basal cell carcinoma
Angioma Bowen’s disease Squamous cell carcinoma
Dermatofibroma Lentigomaligna Keratoacanthoma
Fibroma molle Kaposi sarcoma
Myxoid cyst Inoperable melanoma metastases
Molluscum contagiosum
Hidradenitis suppurativa [72]
Idiopathic guttate hypomelanosis [73]
Keloid, hypertrophic scar
Lentigo solaris
Pyogenic granuloma
Sebaceous hyperplasia
Seborrheic keratosis
Warts
Xanthelasma palpebrarum [74]
Table 1. Different indications of cutaneous cryotherapy [6, 7, 10, 28, 36, 43, 54, 65, 69, 70, 71, 75].
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decade (2008–2016). Additionally, it has been shown that the cryotherapy has lower cost than 
radiotherapy in patients who cannot undergo surgery in non-melanoma skin cancers. The 
average age increase in the second decade is also directly proportional to the increase in non-
melanoma skin cancers [6]. For these reasons, the frequency of cryotherapy application in 
premalignant and malignant disorders may have been increased step by step over the years. 
In this chapter, premalignant and malignant cutaneous disorders have been mainly focused.
Figure 1. (a) Seborrheic keratosis in the right arm, (b) one cycle for 5–10-s freezing time via spray method, (c) before the 
second session of the treatment, reducing in size and fading in pigmentation of lesion.
Figure 2. (a) Verruca plantaris in the sole of right foot, (b) two cycles for 15–20-s freezing time via spray method, (c) after 
2 weeks, reduction in width and induration of lesion.
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4.1. The use of cryotherapy in premalignant skin lesions
4.1.1. Actinic keratosis
AKs are common lesions consisting of epidermal keratinocytic dysplasia that are caused by 
chronic sun exposure. They are the most common premalignant skin lesions and clinically 
characterized by slow-growing, <1 cm, scaly, or hyperkeratotic papules in the areas exposed 
to the sun such as bald scalp, face, forearms, and hands. AKs are of public health importance 
because their presence is associated with the ability to progress to squamous cell carcinoma 
(SCC), especially when they are numerous and have coalesced into an area with severe photo-
damage. Nevertheless, lesions occasionally have spontaneous remission. Utility of the cured 
AKs reduces the metastases, death ratio, and health economic expenditure [8–10].
Dermatologists have been treating patients with AKs for many years with cryotherapy. 
Treatment of these lesions with a simple and inexpensive method prevents converting non-
melanoma skin cancers (especially SCC), which may be more complicated in the future. 
According to an Italian consensus, it is the first treatment option for AK patients with a high 
degree (Olsen 3) of clinical severity [11]. On behalf of the British Association of Dermatologists 
Therapy Guidelines, cryotherapy is a recommendation strength belonging to A group, which 
means there is good evidence to support the use of the procedure [10].
There was no clear consensus on the cryotherapy method of AK treatment all over the world. 
Numerous variables can influence the success of cryotherapy: the skill and experience of the phy-
sician, freezing time, freezing depth, the pressure of the liquid nitrogen set, the size of the orifice 
on the device, the distance between the lesion, the number of sessions, size, and the presence of 
hyperkeratotic lesions [12–14]. To get a point of view, Zouboulis published the meta-analysis via 
26 studies which compared the regional regimens; they declared that the response rate depends 
on the clinicians’ technique, freezing time, and extended area [13].
In this chapter, we focus on the most suitable method. As we wish to enlighten, we have 
evaluated a large number of group samples. Up to 98.8% cure rate has been reported, but 
more recent data indicate smaller cure rates [15]. Ianhez et al. had cryotherapy for 5–10 s in 
the form of two sessions between 5 and 50 tumors on the arm and face area of 92 patients at 
baseline and after 120 days. The same examiner counted the lesions before the treatment, at 
120th and 300th days. After all, they found 57% reduction of lesion numbers. An interesting 
point of view was that higher education level of AK patients and lower number of lesions 
showed more successful results [12]. If we increase the sample size, Goldberg et al. performed 
a single session for 180 AK lesions for the same time as 5–10 s. At the end of 6 weeks, complete 
recovery was observed for all lesions. Though they occasionally focused on non-hyperkera-
totic lesions, more success rates have been expected also due to freezing depth reaching the 
underlying lesions [14]. Figure 3 shows the result of one-cycle cryotherapy of a patient with 
bowenoid AK on the third week.
By the way, authors also investigated the freeze time for line of best fit. An article was inves-
tigated in Australia where 90 adult patients who had 421 eligible AK lesions were cured by 
cryotherapy. They found that higher freezing time is correlated with the higher complete 
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response of the lesion. Especially, the rates were 39% for 5 s, 69% for higher than 5 s, and 83% 
for higher than 20 s. If they achieved a regression analysis, they suggested the best time for 
the freezing time to be between 10 and 15 s as mentioned with maximum effect and also with 
minimum adverse effect. A higher than 30 s damages the dermis and causes scarring tissue 
and hypopigmentation [16]. As a common sense of clinicians, even though the exact regime 
does not exist, two cycles are always applied to get more effects.
When cryotherapy was compared with various methods, it has been observed that very dif-
ferent results were obtained. The first retrospective analysis was made in 1999 at 13 centers in 
5 European countries by Szeimies et al. As population extended, 699 AK lesions were selected 
randomly to photodynamic therapy group (367 lesions) and cryosurgery group (332 lesions). 
They appraised that two modalities have similar complete response rates. Neither cryosurgery 
has superiorities to photodynamic therapy nor it has better cosmetic results. From this article, 
the suitability of cryotherapy has begun to be analyzed further [17]. Years later, Kaufman et 
al. also support this hypothesis in their reports involving more lesions [18]. Freeman et al. col-
lated three groups of AK patients receiving photodynamic therapy (88 patients), cryotherapy 
(89 patients), and placebo (23 patients). The lesion response rates were found to be 91% in the 
photodynamic therapy group, 68% in the cryotherapy group, and 30% in the placebo group. 
As a result, photodynamic therapy has been considered as a better option than cryotherapy 
for complete lesion response as well as cosmetic outcome [19].
From a point of view, some authors analyzed the other optional modalities. From 1 to 3 years, 
clinical improvement of patients with 373 AK lesions treated by cryotherapy or 5-fluoroura-
cil per group was investigated in Florida. As a result, cryotherapy was found to be doubly 
effective than 5-fluorouracil treatment when considering long-lasting comparability and also 
better cosmetic outcomes [20]. In addition, the efficacies of three different treatment modali-
ties in patients with multiple AK lesions were compared by Krawtchenko et al. Nearly equal 
number of patients took one cryotherapy session, twice a day topical 5-fluorouracil during 4 
Figure 3. (a) Bowenoid AK lesion on the maxilla, (b) two cycles for 15–20-s freezing time via spray method, (c) before the 
third session of the treatment, reduction in size, erythema, and hyperkeratosis.
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weeks and topical imiquimod three times per week for 4 weeks. Patients were analyzed for 
clinical and histopathological evaluation at the 12th month. They could not determine the 
correlation between histopathological improvement (32%) and clinical improvement (68%) 
with the cryotherapy method. According to these values, half of the cases did not cure com-
pletely. Despite this, topical imiquimod application was the most effective method, and that 
also clinical (83%) and histopathological (73%) recovery rates were consistent with each other. 
Additionally, the patients’ satisfaction ratio was found to be significantly higher than the 
cryotherapy and 5-fluorouracil application. They considered that 5-fluorouracil treatment is 
not acceptable for AK patients, howbeit topical imiquimod would be the top choice rather 
than cryotherapy [21].
To get another point of view, authorities have been seeking the correct combined treatment 
for AK patients for many years. Combination treatment modalities were inquired to manage 
both the lesion-directed and field-directed therapies. Regarding this, it is logical to combine 
with frequently used topical therapies including 5-fluorouracil, imiquimod, ingenol mebutate 
0.05% gel, and diclofenac gel. All these agents cause some degree of localized inflammatory 
skin reaction mediated through a variety of biochemical pathways (interference with DNA 
synthesis, modification of immune response, and increased apoptosis through cyclooxygen-
ase inhibition) and lead to elimination of the AK lesions [9]. Generally, the lowest irritation 
side effect has been seen with diclofenac gel treatment. As we consider to compare between the 
utility of combined or monotherapy; Berlin and Digel applicated 3% diclofenac gel two weeks 
later than the cryosurgery and they had more adequate results than monotherapy [22]. After 
that, an article made in Italy enrolled 175 patients to configure out the results of monother-
apy, cryotherapy, or 3% diclofenac gel, and combined therapy. The first group administered 
diclofenac gel twice a day for 12 weeks. The second group received two cycles of cryotherapy 
followed by diclofenac gel for 8 weeks. The last group was administered with two cycles of 
cryotherapy two times for 1 month. Nearly equal patients followed up for 2 years. They found 
that the first and third groups showed similar results but the response rate of the first group 
was slower. Besides that, the second group showed most effective results of nearly 100% of 
full recovery. That patients answered response for life quality index and so they responded 
cryotherapy has sufficiently improved the life quality index [23]. Clinicians should choose 
the modalities that are easy, effective, and not time consuming. Mastrolonardo et al. focused 
on the difficult recurrent AK lesions in a small group. They applied 3% diclofenac gel for 12 
weeks so that the mean number reduced from 8 to 1. After that, they cured cryotherapy each 
4 weeks for residual ones. For 10 months, no lesions were observed. They suggested that this 
combination therapy is remarkable for elder patients who show poor cooperation and recur-
rent multiple lesions [24]. Hashim et al. examined 16 patients who had cryotherapy; after that, 
half of them received ingenol mebutate 0.05% gel sequentially for 3 days. Although combined 
treatment had more side effects profile, which is also tolerable, statistically significant reduc-
tion of the lesions had also been observed [25]. In order to promote quantitative analysis for 
the validity of cryotherapy and 5-flurouracil, combination treatment was made in 2004 firstly. 
A sample size of 70 patients per treatment group who took 5-flurouracil regime for 1 week and 
residual lesions are treated with cryotherapy after 4 weeks. Jorizzo et al. calculated the pro-
portion of validity with combined therapy. As a conclusion, they found significant difference 
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between combined therapy and monotherapy for 6 months. They mainly suggested that com-
bined therapy is capable of increasing lesion-free period [26]. In another study, two groups 
included 30 patients with cryotherapy and 5-flurouracil cream of 0.5%, and combination treat-
ment efficacies were compared. After the application of cryotherapy, they used 5-flurouracil 
cream once daily for 1 week. Besides that, they followed up for 26 weeks and claimed that no 
significant difference was found in terms of effectiveness. Despite the fact that adverse effects 
of 5-flurouracil cream have been more commonly observed [27], recent research has shown 
that ingenol mebutate 0.05% gel and cryotherapy combination would be the future model for 
these patients [25]. In conclusion, clinicians should decide case by case due to age, health-care 
conditions, contraindications, and availability in AK cryotherapy.
4.1.2. Bowen’s disease
Bowen’s disease is characterized by enlarging well-demarcated erythematous plaque with an 
irregular border and crusting or scaling surface. It is a form of in situ SCC which behaves dif-
ferently such as partial progression, minimal invasion, or spontaneous regression [28].
Plaza Lanza et al. compared the freezing ratio through the lesion and found that a single cycle 
is as efficacious as for two cycles [29]. Another article conducted by Holt found that they also 
have the same success using single 30-s cycle [30]. Graham and Clark reported one recurrence 
in 30 patients treated with a single period with the longest time as at least 90 s [31].
The rate of recurrence has been lower than expected. Recurrent lesions have been mostly 
invaded to dermis and cause SCC. Cox and Dyson demonstrated recurrence in five patients 
(6%) after a minimum of 1-year follow-up; one of these had a focus of invasive cancer [32]. 
Additionally, Morton et al. found two (10%) recurrences in the 1-year follow-up period [33].
In order to make shorter total imiquimod bout and milder cryotherapy effects compared with 
corresponding monotherapies, Gaitanis et al. published a series consisting of eight cases. 
They used two cycles of cryotherapy along meanly 15 s followed by the application of daily 
topical imiquimod. No recurrence was seen during the 6-month follow-up [34].
Ahmed et al. aimed to compare two strong options in patients with Bowen’s disease, which 
occasionally mainstays in the lower leg region. Thirty-six patients were treated with cryo-
therapy via spray method giving two freeze-thaw cycles, each freeze cycle being maintained 
for 5–10 s. Forty-four patients were therapied with curettage and cautery, the margins beyond 
least 3-mm of clinically lesion-free skin area. As a result, curettage and cautery is a better 
modality because of shorter healing time, lesser pain evaluation, and fewer recurrence rates 
with significant differences [35].
4.1.3. Lentigo maligna
Lentigo maligna is a melanoma in situ which includes malignant cells but do not show inva-
sion. The main reason of that is the long-term sun exposure, which also increased the risk 
of non-melanoma skin cancers. If middle-aged and elderly patients have larger than 1-cm 
atypical pigmented macular lesions, not in smooth surfaces, mainstays usually on the head 
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and neck should be checked up by the clinicians. There is a risk of conversion to malign 
melanoma, and patients should be advised to undergo the surgery. As mentioned earlier, the 
mechanism of extinction between melanocyte of −4 to −7°C has formed the basis of the cryo-
therapy method in melanoma patients. However, in this method, the inability to scientifically 
determine the depth limit of the intervention restricts the number of patients. Beyond this 
reason, it is recommended to implement two cycles, for a long time and at least a distance of 
1 cm from the lesion [36].
In a study conducted by Kuflick and Gage, 30 patients who had been diagnosed with lentigo 
maligna were treated with cryotherapy. At the end of the 3-year follow-up, only two lesions 
(6%) recurred [37]. In Brazil, 18 patients were diagnosed clinically and histopathologically 
as lentigo maligna was cured with cryotherapy by Moraes et al. Two freezing cycles were 
applied for 1 min each separated by thaw cycle of at least 2 min on a single session, and they 
also used spray method beyond a 1-cm area of vision border. In a 5-year period, they followed 
up at 6-month intervals. No recurrences or metastases were observed in any patient [38].
A case report is evaluated to propose cryoimmunological treatment of cryotherapy with imiqui-
mod application in lentigo maligna lesions by Bassukas et al. A 78-year-old man who had been 
denied surgery was treated with 5% imiquimod cream once daily for 3 weeks. When erythema 
occurs, without cessation of the cream, they continued with cryotherapy via 20 s for two cycles. 
One year later, a cross check of the lesion was done, and they could not see any malignant 
cells. The patient became lesion free for 26 months after the treatment. They supposed that this 
combination therapy could be encouraging for lentigo maligna [39]. However, more research is 
needed as there are not many studies conducted on a sufficient number of people.
4.2. The use of cryotherapy in malignant skin lesions
4.2.1. Basal cell carcinoma
Basal cell carcinoma (BCC) is the most common cancer worldwide, which belongs to non-mel-
anoma skin cancer group with SCC. BCC behaves as a slow-growing tumor impacting locally 
destructive cells and causing disfiguration for the metastasis that is very rare. Specifically, 
renal-transplant patients have an increased risk of developing BCC compared with the general 
population. Governments should keep in mind that treatment options should be increased to 
get either health or economic profits. As all you know, the gold standard is Mohs surgery, but 
as elderly people are not appropriate for this surgery, other methods should be used. The last 
publications have a few questions. According to the characteristic of the tumor, should elderly 
people prefer surgery or symptomatic destruction or is screening enough? [40–42].
Superficial and nodular BCCs have relatively well-defined borders, while morpheiform, 
micronodular, trabecular, infiltrative, and basosquamous BCCs are often irregular borders 
and are also more aggressive. The most commonly used approach of low-risk BCC (e.g., 
superficial BCC, nodulo-ulceratif BCC) is cryotherapy. The goal of the treatment is that clini-
cians should assess the margin of the lesion for complete removal. Because of that, invasion 
through the dermis, recurrent and aggressive types, larger than 2-cm lesion size and high-risk 
anatomic positions are contraindications of cryotherapy [43].
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Compared with surgery, there are significant missing aspects. The most important ones are 
higher recurrence rates than surgery, lack of histologic confirmation of malignancy removal, 
recurrent carcinoma may be seen, hypertrophic scarring, and post-inflammatory pigment 
changes may occur. Nevertheless, there are some advantages also such as easy to apply, capa-
ble for elderly people, postoperative care not required, and life quality not affected [40].
Kuflik managed the widest and longest research in this regard, and overall 30-year cure rate 
was 98.6%. In this report, the freezing time and lesion width differ from 40 to 90 s and 1–1.5 cm, 
respectively. The cancer cells have been destroyed in the range of −50 to −60°. The most capable 
and acceptable procedure achieved satisfactory results. They also had a chance to follow-up 
the recurrence of lesions, so they declared that a 5-year cure rate of 522 cases was 99.0% [44]. 
Zacarian et al. reported an overall cure rate of 97.3% in 4228 non-melanoma skin carcino-
mas [45]. Samain et al. only focused on the mid-face BCC lesions and they investigated the 
5-year recurrence ratio. They analyzed 138 patients with 144 BCC lesions and they presented 
94% lesion-free ratio for 5 years. With reference to that, morpheiform BCC, which is theoreti-
cally a contraindication of cryosurgery, decreases the success ratio. Also, 55 lesions had curet-
tage before cryotherapy that aims to increase the success rate by going deep into the lesion 
[46]. An article from Egypt used a different technique via intralesional cryoneedle, which had 
significant response rates and excellent outcomes as minimal or without scarring, erythema, 
and pigmentation changes for nodular and superficial BCC lesions [47]. Recently, one of the 
largest, prospective long-term follow-up series was conducted by Lindemalm-Lundstam and 
Dalenbäck. Like recent reports, they also found 97% complete response and good cosmetic 
results with the curettage and cryosurgery [48].
Actually in routine clinical practices, two cycles were applied to BCC lesions. Additionally, 
thaw time is approximately three times longer than freezing time to share out the lesion [13]. 
According to oncology guidelines, two freeze–thaw cycles with a tissue temperature of −50°C 
are recommended [49]. In order to estimate the reliability of sequence number, Mallon et al. 
treated 83 facial lesions with either one thaw 30-s cycle or second thaw 30-s cycle. They found 
that a double thaw cycle (95.3%) reliability ratio was higher than one cycle (79.4%) but also an 
interesting point is that one cycle is enough for trunk lesions [50].
Cryotherapy is an old but popular method for BCC treatment; there are some positive and 
negative value comparisons with other modalities. Kuijpers et al. compared a 5-year cure rate 
with either cryotherapy or surgical excision with small group, and they did not find statisti-
cally significant reduction of lesion number when surgical excision is chosen. Besides that, 
preferable reason for cryosurgery is better cosmetic outcomes than surgery. Regarding this, 
cryosurgery wounds generally heal with minimal tissue contraction and atrophy or scarring 
tissue is not commonly seen, resulting in good cosmetic results [51].
Actually, combined therapies, which were induced by immunological mechanism, are not 
used in non-melanoma cancers. Some authors worked on cryosurgery combination modali-
ties such as photodynamic therapy or imiquimod cream once daily. Nakuci and Bassukas 
daily applied 5% imiquimod cream for 5 weeks, and at the second week, they performed cryo-
surgery. All 24 patients including 36 BCC lesions were satisfied with the cosmetic outcome 
and expressed their preference for this immunocryosurgery modality again as future choice 
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in the case of a tumor relapse [52]. On the other hand, Wang et al. found that photodynamic 
therapy and cryosurgery are comparable concerning efficacy but photodynamic therapy has 
better cosmetic results via assessment of a phase 3 clinical trial [53].
As a result of previous reports, cryosurgery is an effective method for BCC lesions with excel-
lent cosmetic outcomes, causes higher life quality, and also is a practical approach that can 
implement in office conditions. Especially, superficial and nodular BCC lesions are suitable 
for this treatment. Future studies should focus on optimization of the treatment strategy for 
BCCs to administer standard immunocryosurgery.
4.2.2. Squamous cell carcinoma
SCC is the second most common cancer in the non-melanoma skin cancer class. SCC originates 
from keratinocytes due to cumulative sun exposure of skin. The lesions appear as papules or 
plaques which classified by skin-colored or pink, and smooth or hyperkeratotic. Ulceration 
may be present. The characteristic of SCC lesions is a high risk of distant metastasis causing 
higher mortality rates [54, 55].
SCCs are the most common malignancies in organ-transplant recipients. In immunocompro-
mised patients, despite the clinical subtypes, it should be regarded as high-risk lesions. A 
survey was performed by dermatologists who treated organ-transplant recipients with squa-
mous cell carcinoma. They first choose Mohs surgery among the patients and cryosurgery 
[56] as the second common therapy.
Curettage and cryosurgery arise from a variation of electrodessication and curettage, and 
offer a high cure rate for carefully selected superficial non-melanoma skin cancers. Peikert 
choose four subtypes of facial tumors consisting of superficial BCC (81 lesions), superficial 
BCC with papillary dermal invasion (2 lesions), SCC in situ (11 lesions), and SCC with papil-
lary dermal invasion (6 lesions) which are smaller than 2 cm. They applied curettage after 
that one cycle 10-s cryotherapy, which has lesser freezing time for routine practices among 
the residual tissues. During the 5-year experience, only one recurrence of a superficial BCC 
on trunk was seen among 100 tumoral lesions [57]. For same samples, Nordin worked on 
a specific location as an auricula. They performed two sequence cryosurgery and curettage 
method. For 1-year follow-up, they did not see any metastasis and only one recurrence was 
determined in 60 non-melanoma skin cancer lesions [58].
Gonçalves  described a new method of cryosurgery named as fractional cryosurgery. He 
dispensed hydrophilic gel between the center of the tumor and caused easing the calorie 
transfer. A cryoprobe was applied at the center of the tumor and did not require extending 
safety margin. A normal cryosurgery technique is based on freezing spray, which starts 
from the peripheral and goes through the center of the lesion. Despite this, they cured nine 
SCC lesions during the follow-up, which was 1 year for one patient and between 3 and 6 
years for the remaining patients. They suggested that no recurrence was statistically signifi-
cant; due to this, SCC lesions must be treated more aggressively. They also mentioned that 
larger than 15 mm of lesion width is required for another treatment in non-melanoma skin 
cancers [59].
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It has been mentioned that keratoacanthoma should be accepted as low-risk SCC so that it has 
to be treated as SCC. The defining characteristic of keratoacanthoma is a symmetric inflam-
matory nodula with ulcerative debris originating from pilosebaceous glands. Although it has 
spontaneous regression also over 4–6 months, metastasis risk of SCC is enough to get ade-
quate treatment. Some authors contented that this is a subtype of SCC, also [60, 61].
Chronic radiodermatitis can cause keratoacanthoma in professional physicians who did not 
protect themselves from the chronic X-ray exposure. Conejo-Mir et al. worked on noninvasive 
SCC lesions regard as keratoacanthoma  which located at the finger. They applied two-cycle 
30-s cryotherapy for six patients. During 2 years of follow-up, no recurrence was seen and also 
the most relevant issue is that finger mobility had been protected in all patients [62].
Lee et al. reported using intralesional cryotherapy technique in four elderly patients with ker-
atoacanthoma. After the local anesthesia, an 18-gauge needle was inserted into the lesion and 
two cycles were applied beyond 30–60 s. If the residual lesion was presumed, they also used 
spray cryotherapy for one to three cycles. All lesions had complete remission in 2 months. 
They argued that small lesions as smaller than 1 cm could have been curable. Intralesional 
method is superior than the other types due to cosmetic outcomes such as absence of hypopig-
mentation. However, it would be contraindicated in the anatomic locations where has risk of 
poor healing due to insufficient circulation [63].
A published case report regards subungual SCC treated first with Mohs surgery after which 
the residual tissue is destroyed via cryotherapy as two cycles in 90 s. In order to protect tissue 
integrity and phalanx function, using cryosurgery as an adjuvant may improve cure rates in 
some cases of SCC [64]. Cryosurgery is one of the suitable options when other options are not 
appropriate or adjuvant modality for highly invasive non-melanoma skin cancers.
4.2.3. Kaposi sarcoma
Kaposi sarcoma is a vascular tumor that has brownish red to bluish red cutaneous nodules 
that tended to enlarge into dome-shaped tumors. There are variable modalities used for the 
treatment of Kaposi sarcoma such as surgery, chemotherapy, cryotherapy, electrosurgery, 
laser, and radiation therapies.
Kutlubay et al. investigated 30 patients with Kaposi sarcoma in a retrospective cohort study. 
Nineteen (63%) of them completed response to cryotherapy [65]. In addition, Scheofer et al. 
and Avilés Izquierdo et al. found cryotherapy to be more effective in superficial and small 
Kaposi sarcoma lesions [66, 67].
4.2.4. Inoperable malign melanoma metastases
Although the main treatment option for malign melanoma patients is surgery, different alter-
natives can be used in cutaneous lesions and also metastases as some people could not be 
operated. Rivas-Tolosa et al. applied cryotherapy and topical 5% imiquimod treatment to 
20 patients with locoregional cutaneous metastases of melanoma patients who could not 
undergo surgery. After an average of five sessions, 13 patients (65%) responded to treatment. 
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Eight (40%) of them have complete remission and the remaining five (25%) patients have 
partial response [68]. This is the first published pros and cons of the article regarding the life 
expectancy index of each decision.
5. Conclusion
Cryotherapy is also being discussed as an alternative to surgery in patients with premalig-
nant or malignant skin lesions. The frequency of cryotherapy application has been increased 
step by step over the years correlated with older ages when such lesions occasionally occur. 
Response rates usually depend on the clinicians’ technique, freezing time, and extended area. 
Mainly, non-hyperkeratotic lesions have more successful rates due to freezing depth reaching 
the underlying lesions. It is the first treatment of choice for AK patients. The authors com-
pared the efficacy of modalities and they suggested that topical imiquimod or photodynamic 
therapy would be better choice rather than cryotherapy. Nevertheless, recent researches have 
shown that ingenol mebutate 0.05% gel and cryotherapy combination would be the future 
model for AK patients. Another premalignant lesion is Bowen’s disease, which has also a 
higher risk of converting non-melanoma skin cancer and could be treated by cryotherapy, but 
cryotherapy-combined modalities (5-fluorouracil cream, curettage, and cautery) showed bet-
ter results than monotherapy. An interesting point is that lentigo maligna patients are cured 
by cryotherapy as an alternative for surgery. In non-melanoma skin cancers, cryotherapy is 
an effective method with excellent cosmetic outcomes, thereby causing higher life quality. It 
is practical approach for patients who cannot undergo surgery that can implement in office 
conditions. Negative values of cryotherapy are considered as lack of histologic confirmation 
of malignancy removal, recurrent carcinoma may be seen, hypertrophic scarring, and post-
inflammatory pigment changes may occur. Especially, superficial and nodular BCC lesions 
are suitable for this treatment. High risk of distant metastasis mostly of SCC lesions have 
limited the indications of cryosurgery. Regarding this, well-differentiated SCCs such as ker-
atoacanthoma or SCC in situ lesions have benefits for this modality. Besides that, limited 
study has shown that cryotherapy could be an alternative treatment for Kaposi sarcoma or 
locoregional cutaneous metastasis of melanoma lesions. Cryotherapy is one of the suitable 
options when other options are not appropriate or adjuvant modality for highly invasive non-
melanoma skin cancers. As a conclusion, future studies should focus on optimization of the 
treatment strategy in right-selected multitudinous populations to administer standard cryo-
therapy guidelines.
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